Comparing the efficacy of five first-line treatment regimens for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials

Author:

Jiang Shan1,Xu Ximing1,Xu Yangtao1,Liu Xin1,Chen Wenliang1

Affiliation:

1. Renmin Hospital of Wuhan University

Abstract

Abstract Background: To find ideal treatment regimens in unresectable hepatocellular carcinoma (u-HCC) are clinically important. This study evaluated the efficacy of five first-line regimens in u-HCC patients at 6-, 12-, 18-, 24-, and 30-month overall survival (OS) to provide reference for rational clinical treatment. Methods: We performed a systematic search using five databases. Screening and including qualified randomized controlled trials (RCT) regarding to the first-line regimens for unresectable HCC. Odds ratios (OR) were generated for dichotomous variants by network meta-analysis. The primary endpoint was OS, and the secondary endpoint was progression-free survival (PFS). The software implemented was STATA 17.0 MP. Results: Eventually, a total of six RCTs with five first-line regimens were included. HAIC-FO (OR=9.78, 95%CI: 4.21 to 22.69) was significantly superior to sorafenib on OS at 18th month. Concurrently, HAIC-FO (SUCRA=100%) had the highest ranking compared with the rest regimens. Atezolizumab plus bevacizumab (OR=5.13, 95%CI: 2.28 to 11.54) showed significantly better efficacy compared with sorafenib on PFS at 12th month. Synchronously, atezolizumab plus bevacizumab (SUCRA=87.3%) had the highest ranking. Conclusion: For patients with u-HCC, The optimal regimen we recommend is treating with HAIC-FO until 18th month, followed by sequential therapy with donafenib. Furthermore, we need more head-to-head trials to confirm these findings.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3